Back to top
more

Intellia Therapeutics (NTLA)

(Delayed Data from NSDQ)

$15.67 USD

15.67
8,845,931

+0.47 (3.09%)

Updated Jun 18, 2026 03:59 PM ET

After-Market: $15.63 -0.04 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 38% (153 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened

by Zacks Equity Research

Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.

Zacks Equity Research

Vertex Q3 Earnings Beat, Stock Down as Casgevy Sales Disappoint

by Zacks Equity Research

VRTX tops Q3 earnings and revenue estimates on strong Trikafta and Alyftrek sales, but shares slip as Casgevy sales disappoint.

Zacks Equity Research

AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales

by Zacks Equity Research

Axsome incurs wider-than-expected Q3 loss but revenues soar 63% on booming Auvelity sales, with Sunosi and the newest drug, Symbravo, aiding the top line.

Zacks Equity Research

TGTX's Q3 Earnings & Revenues Trump Estimates, 2025 View Raised

by Zacks Equity Research

TG Therapeutics beats third-quarter estimates as a surge in Briumvi sales drives revenues up 92.8% and leads to a higher 2025 outlook.

Sundeep Ganoria headshot

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?

by Sundeep Ganoria

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

Zacks Equity Research

Intellia Gears Up to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

NTLA's third-quarter results are likely to reflect progress on the CRISPR pipeline, with focus on ATTR studies and progress in HAE therapy filing.

Zacks Equity Research

AGIO's Q3 Loss Narrower Than Expected, Pyrukynd Drives Y/Y Revenues

by Zacks Equity Research

Agios posts a narrower-than-expected third-quarter loss as Pyrukynd drives a 44% revenue rise, with potential label expansions on the horizon.

Zacks Equity Research

ANI Pharmaceuticals (ANIP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Emergent Biosolutions (EBS) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Emergent Biosolutions (EBS) delivered earnings and revenue surprises of +983.33% and +20.88%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Kanishka Das headshot

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

by Kanishka Das

Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.